Day: February 28, 2024

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Written by Customer Service on February 28, 2024. Posted in Public Companies.

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen panel discussion can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company striving...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) with nivolumab in registrational Phase 3 first-line advanced cutaneous melanoma trial; PRISM-MEL301 trial to start in 1Q 2024 Multiple clinical readouts expected to start in 2Q 2024 for IMC-F106C from Phase 1/2 clinical trial monotherapy and combination arms; CTA/IND submission for IMC-P115C (PRAME HLA-A02 HLE) and IMC-T119C (PRAME HLA-A24) programs on track...

Southern States Bancshares to Enhance Georgia Franchise With Acquisition of CBB Bancorp

Written by Customer Service on February 28, 2024. Posted in Mergers And Acquisitions.

ANNISTON, Ala. and CARTERSVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) — Southern States Bancshares, Inc. (NASDAQ: SSBK) (“Southern States”), the holding company for Southern States Bank, and CBB Bancorp (“CBB Bancorp”), the holding company for Century Bank of Georgia (“Century Bank”), announced today the signing of a definitive merger agreement under which Southern States would acquire CBB Bancorp. Upon completion, Southern States expects to merge CBB Bancorp with and into Southern States, with Southern States as the surviving entity. Century Bank of Georgia would similarly be merged with and into Southern States Bank with Southern States Bank surviving. The transaction is expected to close in the third quarter of 2024, subject to regulatory approval. Upon completion of the transaction, Southern States Bank is expected to have approximately...

Specialty Silica Market Set to Soar Past USD 10.1 Billion by 2030 | Skyquest Technology

Written by Customer Service on February 28, 2024. Posted in Mergers And Acquisitions.

Dive into the world of Specialty Silica, where we explore its size, share, and growth prospects. Our focus extends to various products, including Precipitated Silica, Fumed Silica, Fused Silica, Silica Gel, and Colloidal Silica. These versatile products find applications in various sectors, such as rubber, agrochemicals, oral care, food industry, desiccants, paints & coatings, and more. Join us as we navigate through this industry, forecasting trends and developments from 2023 to 2030. Westford,USA, Feb. 28, 2024 (GLOBE NEWSWIRE) — The global Specialty Silica market size is expected to reach USD 10.1 billion by 2030 and exhibit a CAGR of 5% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing demand for green and sustainable products in industries like tires and rubber, the...

Nayax Reports Record Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Full year revenue reached $235.5 million, representing 36% YoY growth; recurring revenue up 44% YoY Positive full year cash flow from operations – $8.8 million 2024 full year revenue guidance of $325-335 million, representing 38%+ YoY growth; 2024 full year adjusted EBITDA guidance of $30-35 million(1) HERZLIYA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the fourth quarter and full year 2023. Management Commentary “2023 was a fantastic year for Nayax from both a strategic and financial perspective. The inherent operating leverage in our business model continues to be a key driver of our improving margins, as we progress towards our long-term 2028 target of...

Daktronics, Inc. Announces 2024 Fiscal Third Quarter Results

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

BROOKINGS, S.D., Feb. 28, 2024 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ-DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide, today reported results for its fiscal 2024 third quarter which ended January 27, 2024. Q3 FY2024 financial highlights:Year-to-date product and service orders were $534.4 million(1), an increase of 6.6 percent as compared to $501.4 million in the same period of fiscal 2023; during the third quarter of fiscal 2024, new product and service orders were $192.1 million, a 29.4 percent increase from $148.4 million in the year-earlier period Sales of $170.3 million, a 7.9 percent decrease from the third quarter of fiscal 2023; the year-ago period’s record revenue was driven by high backorder fulfillment as a...

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 – $380 million, representing ~59% year-over-year growth at the midpoint –– Abiprubart Phase 2 rheumatoid arthritis data from Cohort 4 and a new development indication expected in April 2024 –– Cash reserves of $206.4 million expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Feb. 28, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year...

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~ ~ Announced FDA clearance of two Investigational New Drug (IND) applications; Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are expected in the first half of 2024 ~ ~ Announced strategic reorganization to advance multiple clinical-stage programs and deliver $180 million of cost savings over the next three years ~ ~ Cash position of approximately $618 million as of December 31, 2023 expected to fund operations into the second quarter of 2027 ~ LEXINGTON, Mass. and AMSTERDAM, Feb....

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

– Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million – – Net COSELA Revenue Grew 29% in the Fourth Quarter of 2023 to $13.9 Million – – Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in Metastatic Triple Negative Breast Cancer is Estimated to Occur in the Third Quarter of 2024 – – Presented New Analyses Indicating that Patients Who Previously Received Trilaciclib in a Clinical Trial Setting Experienced Improved Overall Survival with Subsequent Anticancer Therapies – – Provided Initial Results from Phase 2 Trial in Combination with a TROP2 Antibody-Drug Conjugate Indicating Improvements in Overall Survival...

Chart Industries Reports 2023 Fourth Quarter and Full Year Financial Results

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) (“Chart”) today reported results for the fourth quarter and full year ended December 31, 2023. Results shown are from continuing operations. When referring to the fourth quarter 2022, full year 2022 or any quarter of 2023 comparative period, all metrics are pro forma for continuing operations of the combined business of Chart and Howden; this includes Howden (includes the stub period of January 1, 2023 to March 16, 2023 where we did not own Howden), excludes Roots™, and excludes the impacted periods of November and December in 2022 of American Fan, Cofimco, and CryoDiffusion divestitures. Fourth quarter 2023 highlights (as compared to the fourth quarter 2022 pro forma):Record orders, backlog, sales, gross profit, gross profit margin, operating...

Day: February 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals